Page 132 - HIVMED_v21_i1.indb

Page 3 of 3 Scientific Letter

17
COVID-19 and HIV. This coincides with activities of the Data availability statement
third Specialised Technical Committee on Health,
Population and Drug Control (STC-HPDC-3) held in Data sharing does not apply to this article, as no new data
Cairo in August 2019. Sixteen African countries (Algeria, were created.
Benin, Chad, Ghana, Madagascar, Mali, Morocco,
Rwanda, Saharawi Arab Democratic Republic, Senegal, Disclaimer
Tunisia, Seychelles, Niger, Guinea, Sierra Leone and The mentioned opinions expressed in this article are those of
Burkina Faso) officially signed the treaty. The AMA is the authors and do not necessarily reflect the official policy or
considered to be the first continental initiative to integrate position of any affiliated agency of the authors.
the regulations of medicines and medical products
thereby ensuring the provision of safe and effective drugs References
and medical products to the people. The treaty also aims
to strengthen Africa’s capacity to produce medicines by 1. Cordie A, El-Kotamy M, Esmat G. Antiretroviral therapy optimisation in the time
utilising available production capacity and unifying of COVID-19: Is it really different in North and South Africa? S Afr J HIV Med.
2020;21(1):a1118. https://doi.org/10.4102/sajhivmed.v21i1.1118
standards and product registration across the continent. 2. Shawky S, Soliman C, Kassak KM, Oraby D, El-Khoury D, Kabore I. HIV surveillance
Such a treaty will allow drugs manufactured or registered and epidemic profile in the Middle East and North Africa. J Acquir Immune Defic
in one African country to be deployed elsewhere on the Syndr. 2009;51(Suppl 3):S83-S95. https://doi.org/10.1097/QAI.0b013e3181aafd3f
continent without further regulatory constraints. This 3. Haakenstad A, Moses MW, Tao T, et al. Potential for additional government
spending on HIV/AIDS in 137 low-income and middle-income countries: An
will in turn widen the availability and variety of drugs economic modelling study. Lancet HIV. 2019;6(6):e382-e395. https://doi.org/
and augment competition amongst API providers to 10.1016/S2352-3018(19)30038-4
ensure that medicines can be offered at an optimum and 4. Global AIDS monitoring 2019, country progress report, Egypt [homepage on the
Internet]. [cited 2020 Sept 26]. Available from: https://www.unaids.org/sites/
affordable price. default/files/country/documents/EGY_2019_countryreport.pdf
5. Explore HIV/AIDS programme, UNICEF Egypt website [homepage on the Internet].
[cited 2020 Sept 26]. Available from: https://www.unicef.org/egypt/hivaids
Conclusion 6. WHO Updated recommendations on first-line and second-line antiretroviral
regimens and post-exposure prophylaxis and recommendations on early infant
The COVID-19 pandemic requires both a short- and long- diagnosis of HIV, interim guidance [homepage on the Internet]. [cited 2020 Sept 26].
term strategy to overcome the anticipated shortages of Available from: https://www.who.int/hiv/pub/guidelines/ARV2018update/en/
HIV-related healthcare services at national level. In 7. WHO Update of recommendations on first- and second-line antiretroviral
regimens [homepage on the Internet]. [cited 2020 Sept 26]. Available from:
parallel with this, multisectoral international solidarity https://www.who.int/hiv/pub/arv/arv-update-2019-policy/en/
and collaboration with global stakeholders needs to be 8. WHO newsroom, access to HIV medicines severely impacted by COVID-19 as AIDS
response stalls [homepage on the Internet]. [cited 2020 Sept 26]. Available from:
continued and fostered to achieve the 90-90-90 UNAIDS https://www.who.int/news-room/detail/06-07-2020-who-access-to-hiv-
HIV-elimination goals and manage COVID-19 medicines-severely-impacted-by-covid-19-as-aids-response-stalls
successfully. 9. UNAIDS press release, COVID-19 could affect the availability and cost of
antiretroviral medicines, but the risks can be mitigated [homepage on the
Internet]. [cited 2020 Sept 26]. Available from: https://www.unaids.org/en/
Acknowledgements resources/presscentre/pressreleaseandstatementarchive/2020/june/20200622_
availability-and-cost-of-antiretroviral-medicines
Competing interests 10. Hassany M, Abdel-Razek W, Asem N, AbdAllah M, Zaid H. Estimation of COVID-19
burden in Egypt. Lancet Infect Dis. 2020;20(8):896-897. https://doi.org/10.1016/
S1473-3099(20)30319-4
The authors have declared that no competing interests exist. 11. Afro WHO health topics [homepage on the Internet]. [cited 2020 Sept 26].
Available from: https://www.afro.who.int/health-topics/hivaids
Authors’ contributions 12. Martial NP, Sieleunou I. An appeal for large scale production of antiretroviral drugs in
Africa. Pan Afr Med J. 2016;25(261):18. https://doi.org/10.11604/pamj.2016.25.
18.10658
All authors contributed equally to this work. 13. Access to antiretroviral therapy in Africa, status report on progress towards the
2015 targets [homepage on the Internet]. [cited 2020 Sept 26]. Available from:
https://www.unaids.org/sites/default/files/media_asset/20131219_
Ethical consideration AccessARTAfricaStatusReport Progresstowards2015Targets_en_0.pdf
14. Africa development information [homepage on the Internet]. [cited 2020 Sept 26].
This article followed all ethical standards for research Available from: http://www.afri-dev.info
without direct contact with human or animal subjects. 15. COVID-19 worldmeter [homepage on the Internet]. [cited 2020 Sept 26]. Available
from: https://www.worldometers.info/coronavirus/
16. Gaye B, Khoury S, Cene CW, et al. Socio-demographic and epidemiological
Funding information consideration of Africa’s COVID-19 response: What is the possible pandemic course?
Nat Med. 2020;26(7):996-999. https://doi.org/10.1038/s41591-020-0960-y
This research received no specific grant from any funding 17. African Medicine Agency (AMA) Treaty [homepage on the Internet]. [cited 2020
agency in public, commercial or not-for-profit sectors. Sept 26]. Available from: https://au.int/en/pressreleases/20200205/african-
medicine-agency-ama-treaty

http://www.sajhivmed.org.za 124 Open Access